• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Family Health Corner

News That Affects Your Family's Health

FAMILY HEALTH CORNER
News That Affects Your Family's Health

  • Home
  • About/Contact
  • CHILDREN
  • HEALTH NEWS/TRENDS
  • INSURANCE
  • MEN
  • MENTAL HEALTH
  • WOMEN

Pfizer-BioNTech COVID-19 Vaccine Receives Full FDA Approval – Consumer Health News

August 23, 2021 by Staff Reporter

MONDAY, Aug. 23, 2021 (HealthDay News) — The U.S. Food and Drug Administration on Monday granted full approval for the Pfizer-BioNTech COVID-19 vaccine.

The vaccine will now be marketed as Comirnaty and is fully approved for the prevention of COVID-19 in individuals 16 years and older. The vaccine remains under emergency use authorization for individuals ages 12 to 15 years and for administration of a third dose in certain immunocompromised individuals.

“While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated,” Acting FDA Commissioner Janet Woodcock, M.D., said in an agency press release. “Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.”

The FDA decision to fully approve Comirnaty was based on a review of updated data from the clinical trial that supported the emergency use authorization. The updated data included a longer follow-up duration and a larger clinical trial population of 20,000 individuals who received the vaccine and 20,000 who received placebo. Based on the updated results, the vaccine was 91 percent effective in preventing COVID-19.

The review also included updated safety data on 22,000 people who received the vaccine and 22,000 who received placebo, more than half of whom were followed for at least four months.

The agency also conducted an evaluation of postauthorization safety surveillance data regarding the risks for myocarditis and pericarditis following receipt of the Pfizer-BioNTech COVID-19 vaccine. They found the data demonstrate increased risks, especially within the seven days following the second dose and with a higher risk among men younger than 40 years, in particular males ages 12 to 17 years. Data have shown symptom resolution in the majority of individuals, but some have required intensive care support.

The Comirnaty Prescribing Information includes a warning about these risks, but the agency notes that information is not yet available on potential long-term health outcomes. The FDA is requiring Pfizer-BioNTech to conduct postmarketing studies to further evaluate these risks.

More Information

###[ad_2]
Originally Appeared Here

Filed Under: MEN

Primary Sidebar

More to See

Medical startup has Stonington native in mind

Oct. 6—When over 100 people gather on Tuesday, Oct. 12, at Stonington Country Club for the first Andrew Heylmun Invitational golf tournament, they'll … [Read More...] about Medical startup has Stonington native in mind

Walking your way: NAMI hosting virtual walk for mental health this weekend | News, Sports, Jobs

MARQUETTE — There’s never a bad time to think about your mental health: Where it stands, how you can improve it, and where to go for help if you need … [Read More...] about Walking your way: NAMI hosting virtual walk for mental health this weekend | News, Sports, Jobs

18 ft Purple Crush Water Slide Rental

https://abouttobounce.com - BOOK YOUR Inflatable Party Rental from About To Bounce Inflatables, TODAY! Inflatable Bounce House and Inflatable Water … [Read More...] about 18 ft Purple Crush Water Slide Rental

Privacy Policy | Terms and Conditions | About/ Contact
As an Amazon Associate I earn from qualifying purchases.
Copyright © 2022 · FAMILY HEALTH CORNER . Log in